Researchers studying identical twins and laboratory models have found that certain gut bacteria may be linked to MS development.

New clinical trial results show that tolebrutinib reduces the risk of disability progression in non-relapsing secondary progressive MS and is as effective as teriflunomide in relapsing MS.

Researchers have discovered that genetic changes accumulate more rapidly in MS brain lesions than in non-lesion tissue, with distinct patterns emerging in the lesions.

A pilot study has found an existing online cognitive behavioural therapy (CBT) program from Germany is highly acceptable to people with multiple sclerosis (MS) in Australia and achieved reduced levels of MS-related fatigue.

Phase 3 trials did not show a clear advantage of evobrutinib compared to current treatments for people with relapsing MS.

On International Women’s Day, we look at the disproportionate effects MS has on Australian women and the research MS Australia is supporting to address it.